Gilead’s HIV franchise is accelerating, with Yeztugo, Trodelvy, and a stronger pipeline offsetting pressure in Veklury and cell therapy. The stock looks attractive for moderate-risk investors with a medium-term horizon.
Gilead Sciences (GILD) offers a Buy profile for moderate-risk investors with a medium-term horizon. The thesis rests on a durable HIV franchise, accelerating HIV prevention through Yeztugo, improving Trodelvy demand, and a broader pipeline strengthened by the Arcellx, Ouro Medicines, and Tubulis transactions.
The operating evidence is strong. Q1 2026 total revenue reached $7.0B, up 4% year over year, while product sales excluding Veklury rose 8% to $6.8B. HIV sales increased 10% to $5.0B, Trodelvy sales climbed 37% to $402M, and Livdelzi sales more than tripled to $133M. Gilead also raised 2026 product sales guidance to $30.0B to $30.4B.
The trade-off is balance-sheet and execution risk. Gilead carried $22.1B of debt at year-end 2025 against $7.6B of cash, while the announced transactions bring substantial acquired research and development costs. Cell therapy sales fell 12% year over year in Q1 2026, and Veklury sales fell 52%. GILD is therefore not a clean growth stock. It is a cash-generative pharmaceutical franchise attempting to convert HIV strength into oncology and inflammation growth.
Gilead Sciences (GILD) is a U.S.-based biopharmaceutical company headquartered in Foster City, California. Founded in 1987 and listed on Nasdaq since 1992, the company employed approximately 17,000 people and operated marketing subsidiaries in more than 35 countries according to its 2026 Form 10-K.
The business focuses on virology, oncology, and inflammation. Its commercial portfolio includes Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo in HIV; Epclusa, Livdelzi, and Vemlidy in liver disease; Trodelvy in oncology; Yescarta and Tecartus in cell therapy; AmBisome in antifungal treatment; and Veklury for COVID-19.
HIV produced $5.0B of Q1 2026 sales, up 10% year over year. Biktarvy contributed $3.4B, up 7%, while growth in Yeztugo and Descovy supported an 87% increase in the U.S. PrEP business. Management raised 2026 HIV growth guidance to approximately 8% from 6%, even after including an estimated 2% policy-related headwind.
Liver disease generated $767M in Q1 2026, up 1% year over year. Livdelzi was the growth engine, reaching $133M and more than tripling from the prior year. The broader category remains restrained by lower hepatitis C patient starts and inventory movement, so Livdelzi's expansion is important because it adds growth to a mature portfolio.
Oncology product sales reached $810M in Q1 2026, up 7% year over year. Trodelvy supplied the momentum, while cell therapy sales declined to $407M. The divergence matters: Gilead's antibody-drug conjugate franchise is gaining traction, while Kite's established CAR-T products face in-class and out-of-class competition.
Veklury contributed $144M in Q1 2026, down 52% year over year. Gilead's 2026 Veklury guidance remains approximately $600M. The product is now a smaller and declining contributor, which reduces its ability to distort the underlying base-business trend.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Biktarvy remains Gilead's flagship commercial product. Q1 2026 sales were $3.4B, up 7% year over year, and the product held more than 52% share of the U.S. HIV treatment market. Management said Biktarvy has recorded year-over-year share gains in every quarter since launch and remains a leading regimen for treatment-naive and switching patients across major markets.
The strategic value of Biktarvy extends beyond its direct sales. Physicians know the regimen, patients are already embedded in the treatment ecosystem, and Gilead can introduce additional products to the same commercial network. That installed base helps explain why the company expects no major HIV loss-of-exclusivity events until 2036.
Yeztugo is the newer growth engine. Q1 2026 sales reached $166M, up 72% sequentially, and Gilead raised full-year Yeztugo guidance to approximately $1.0B. The company reported approximately 95% U.S. coverage and said 95% of covered individuals can access the product with a $0 co-pay. Early market share leadership in the long-acting injectable switch segment gives Yeztugo a credible path to expand prevention revenue.
Gilead's strongest competitive advantage is the combination of HIV science, commercial scale, and long-acting delivery expertise. Biktarvy anchors treatment, Descovy supports prevention, and Yeztugo extends the franchise into twice-yearly dosing. The Q1 2026 U.S. PrEP market grew approximately 14%, while Gilead's U.S. PrEP business grew 87%, showing that the company is gaining faster than the category.
The pipeline included 47 clinical programs after the Arcellx acquisition. Near-term milestones include an FDA decision for bictegravir plus lenacapavir, or BIC/LEN, with a PDUFA date of August 27, 2026, and an FDA decision for anito-cel with a PDUFA date of December 23, 2026. BIC/LEN targets once-daily treatment for virally suppressed patients, while anito-cel targets relapsed or refractory multiple myeloma.
Gilead is also broadening its technology base. Arcellx added a D-domain binder platform and anito-cel, while Tubulis adds an antibody-drug conjugate platform centered on TUB-040. Ouro adds gamgertamig, a BCMA-CD3 T-cell engager for B-cell-driven autoimmune diseases. These assets do not remove clinical risk, but they give Gilead more opportunities to replace mature revenue streams.
Gilead sells through its own commercial teams, third-party distributors, and corporate partners. In the U.S., approximately 90% of gross product sales have historically flowed through Cardinal Health, Cencora, and McKesson and their specialty distributor affiliates. That channel structure provides reach, but it also creates customer concentration in distribution.
The company directly promotes medicines to physicians, hospitals, clinics, and other healthcare providers. Its international model combines commercial subsidiaries with distributors and partners, allowing Gilead to serve more than 35 countries without relying on one global route to market.
Gilead's 2026 Form 10-K states that it outsources most clinical trial activities to contract research organizations. The company keeps selected start-up activities in-house while relying on external providers for site identification, enrollment, monitoring, program management, and bioanalysis. In cell therapy, the Kite manufacturing network is a strategic asset because CAR-T production requires specialized processes and site coordination.
Gilead participates in several markets with different growth profiles. U.S. HIV treatment grew 2% to 3% in the Q1 2026 presentation, while the U.S. PrEP market grew approximately 14%. That contrast favors prevention, where Yeztugo and Descovy can expand patient access rather than compete only for existing treatment share.
Oncology remains a large but crowded market. Trodelvy sales increased 37% year over year to $402M, and the product was approved in more than 60 countries. Gilead reported statistically significant progression-free survival improvements in first-line metastatic triple-negative breast cancer trials, creating a path to a broader treatment population.
Liver disease is a smaller market for Gilead, but Livdelzi is changing the mix. The product held more than 50% share of the U.S. second-line primary biliary cholangitis market in Q1 2026. A potential label expansion supported by the IDEAL study would give the product access to a larger second-line population.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Gilead's customers include HIV specialists, primary-care physicians, infectious-disease clinics, hospitals, oncology centers, specialty pharmacies, and government and private payers. The treatment profile of Biktarvy creates recurring demand because HIV therapy is taken chronically, while Yeztugo targets prevention patients who value reduced dosing frequency.
Commercial access is a central part of the PrEP opportunity. Gilead reported approximately 95% U.S. coverage for Yeztugo and 95% $0 co-pay access among covered individuals. Those figures support adoption, although the 2% policy-related headwind included in 2026 HIV guidance shows that payer terms remain a material influence on realized revenue.
Oncology customers are more concentrated around specialized treatment centers. Trodelvy and CAR-T therapies require physician familiarity, infusion capacity, patient selection, and reimbursement coordination. Gilead's more than 35-country commercial footprint and Kite's cell therapy infrastructure support those requirements, but the Q1 cell therapy decline shows that infrastructure alone does not prevent competitive share loss.
In HIV, ViiV Healthcare, backed by GSK, Pfizer, and Shionogi, competes through Cabenuva and Apretude. Gilead's more than 52% U.S. Biktarvy share and its Yeztugo launch give GILD scale in both treatment and prevention, but long-acting HIV products make adherence and dosing convenience a direct competitive battleground.
In oncology, Trodelvy competes with products and development programs from Roche, AstraZeneca, Merck, Bristol Myers Squibb, Pfizer, Eli Lilly, and Johnson & Johnson. Trodelvy's 37% Q1 growth and Category 1 NCCN recommendations in first-line metastatic triple-negative breast cancer support its position, but the breadth of the competitor set limits the case for an unrestricted premium valuation.
Kite competes with Bristol Myers Squibb, Novartis, and Johnson & Johnson in CAR-T. Gilead reported Q1 cell therapy sales of $407M, down 12% year over year, citing ongoing in-class and out-of-class competition. Anito-cel is intended to refresh the franchise, with management identifying a $3.5B fourth-line-plus CAR-T market.
The most direct external pressure in the supplied data is U.S. drug pricing policy. Gilead incorporated an approximately 2% headwind into 2026 HIV growth guidance from a drug pricing agreement affecting Medicaid pricing and proposed Affordable Care Act changes. That headwind sits alongside the company's raised 8% HIV growth outlook.
Regulatory timing is equally important. The FDA assigned August 27, 2026, to the BIC/LEN review and December 23, 2026, to the anito-cel review. Gilead also expects regulatory decisions involving Trodelvy, bulevirtide, and Livdelzi during 2026. Each decision carries product-specific clinical and commercial consequences.
The cell and gene therapy environment combines opportunity with manufacturing scrutiny. The FDA announced greater flexibility around certain cell and gene therapy chemistry, manufacturing, and controls requirements in January 2026. That policy direction supports development, while Gilead's reliance on specialized Kite manufacturing keeps operational execution central to the investment case.
$22.1B of debt versus $7.6B of cash leaves Gilead with a leveraged but still manageable balance sheet, especially given its cash-generative HIV base.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 revenue rose 4% to $7.0B and product sales excluding Veklury climbed 8% to $6.8B, showing the core business is still expanding.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 product sales guidance to $30.0B-$30.4B and HIV growth guidance to about 8%, even after a 2% policy headwind.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Gilead’s B valuation reflects a cash-rich pharmaceutical franchise that is not priced like a high-growth biotech, but still depends on HIV durability and pipeline execution.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s price framework points to $157 as fair value, with upside tied to HIV strength and Yeztugo adoption and downside limited by mature cash generation.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Gilead Sciences (GILD) has moved beyond a simple mature-HIV narrative. Biktarvy remains a formidable commercial anchor, Yeztugo is scaling rapidly, Trodelvy is gaining oncology traction, and Livdelzi is building a meaningful liver-disease position. Q1 2026 revenue growth, seven consecutive EPS beats, and raised product sales guidance confirm that the core business is producing.
The next phase depends on capital allocation and pipeline conversion. Debt remains manageable against $10.0B of annual operating cash flow, but the Arcellx, Ouro, and Tubulis transactions increase execution demands. The Buy recommendation therefore rests on disciplined expectations: Gilead does not need every pipeline asset to succeed, but it does need HIV momentum and at least a portion of the oncology and inflammation investments to become commercial growth.
For a medium-term portfolio, GILD combines a relatively defensive cash engine with selected growth catalysts. The valuation is reasonable rather than extraordinary, making $157 the appropriate anchor and lower price levels the more compelling opportunities.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Gilead Sciences, Inc. (GILD) gains 2.6% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook.
Five travel booking stocks are ranked by investment quality, with Airbnb, Expedia, and Tripadvisor showcasing distinct marketplace, OTA, and travel-research models.
U.S. factory orders slipped in June, missing forecasts and signaling softer manufacturing momentum beyond transportation. Still, strong core capital-goods demand tied to AI investment helped offset the weakness, while the ISM index stayed in expansion territory and kept recession fears in check.